N4 Pharma Plc

AIM:N4P Stock Report

Market Cap: UK£2.1m

N4 Pharma Valuation

Is N4P undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of N4P when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate N4P's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate N4P's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for N4P?

Key metric: As N4P barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for N4P. This is calculated by dividing N4P's market cap by their current book value.
What is N4P's PB Ratio?
PB Ratio1.7x
BookUK£1.25m
Market CapUK£2.07m

Price to Book Ratio vs Peers

How does N4P's PB Ratio compare to its peers?

The above table shows the PB ratio for N4P vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average16.2x
CEL Celadon Pharmaceuticals
4.2xn/aUK£10.3m
KNB Kanabo Group
1xn/aUK£5.7m
STX Shield Therapeutics
47.4x84.4%UK£20.7m
FUM Futura Medical
12.2x188.3%UK£95.4m
N4P N4 Pharma
1.7xn/aUK£2.1m

Price-To-Book vs Peers: N4P is good value based on its Price-To-Book Ratio (1.7x) compared to the peer average (16.2x).

Price to Book Ratio vs Industry

How does N4P's PB Ratio compare vs other companies in the GB Pharmaceuticals Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
EAH ECO Animal Health Group
0.6x39.2%US$59.53m
OCTP Oxford Cannabinoid Technologies Holdings
0.6x15.1%US$1.60m
NFX Nuformix
0.1xn/aUS$506.93k
No more companies available in this PB range
N4P 1.7xIndustry Avg. 2.2xNo. of Companies5PB03.67.210.814.418+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: N4P is good value based on its Price-To-Book Ratio (1.7x) compared to the European Pharmaceuticals industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is N4P's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

N4P PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate N4P's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 19:09
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

N4 Pharma Plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emma UlkerAllenby Capital Limited